Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Prana Biotechnology Investor Presentation

June 27, 2018August 16, 2022 Alterity Therapeutics

1_Prana Biotechnology Investor Presentation_2018-0627 final

2018

Post navigation

Prana to commence Phase 1 clinical trial of PBT434 for treatment of parkinsonian diseases

First volunteers dosed in Phase I clinical trial of PBT434, Prana’s lead therapy for parkinsonian diseases

Related Posts

HCW&Co publishes Prana Reach2HD trial report, results “beat expectations”

February 24, 2014August 16, 2022

Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson’s and Alzheimer’s

January 6, 2022August 16, 2022

Prana’s PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration

July 3, 2017August 16, 2022

Recent Posts

Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder
Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023
Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy
Appendix 4C – Q3 FY23 Quarterly Cash Flow Report
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065